Perceptive Advisors LLC grew its holdings in shares of CymaBay Therapeutics Inc (NASDAQ:CBAY) by 14.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 2,685,882 shares of the biopharmaceutical company’s stock after acquiring an additional 335,000 shares during the period. CymaBay Therapeutics comprises 0.8% of Perceptive Advisors LLC’s holdings, making the stock its 29th largest holding. Perceptive Advisors LLC owned about 4.84% of CymaBay Therapeutics worth $24,710,000 as of its most recent SEC filing.
Other hedge funds have also added to or reduced their stakes in the company. Schwab Charles Investment Management Inc. bought a new position in shares of CymaBay Therapeutics during the fourth quarter valued at $115,000. Goldman Sachs Group Inc. bought a new position in shares of CymaBay Therapeutics during the fourth quarter valued at $197,000. Virtu Financial LLC raised its stake in shares of CymaBay Therapeutics by 56.2% during the fourth quarter. Virtu Financial LLC now owns 24,735 shares of the biopharmaceutical company’s stock valued at $228,000 after acquiring an additional 8,899 shares during the last quarter. Sigma Planning Corp raised its stake in shares of CymaBay Therapeutics by 82.0% during the fourth quarter. Sigma Planning Corp now owns 27,300 shares of the biopharmaceutical company’s stock valued at $251,000 after acquiring an additional 12,300 shares during the last quarter. Finally, Wells Fargo & Company MN raised its stake in shares of CymaBay Therapeutics by 7,729.2% during the fourth quarter. Wells Fargo & Company MN now owns 39,146 shares of the biopharmaceutical company’s stock valued at $360,000 after acquiring an additional 38,646 shares during the last quarter. 61.36% of the stock is owned by hedge funds and other institutional investors.
In other news, Director Kurt Von Emster bought 153,846 shares of the stock in a transaction that occurred on Thursday, July 19th. The stock was acquired at an average price of $6.50 per share, with a total value of $999,999.00. Following the completion of the purchase, the director now directly owns 90,000 shares of the company’s stock, valued at $585,000. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 978,140 shares of company stock valued at $11,761,941 in the last three months. 15.10% of the stock is owned by insiders.
CymaBay Therapeutics Inc (NASDAQ CBAY) opened at $14.99 on Monday. CymaBay Therapeutics Inc has a 52 week low of $3.16 and a 52 week high of $15.59. The firm has a market cap of $831.15, a price-to-earnings ratio of -14.70 and a beta of 1.96. The company has a debt-to-equity ratio of 0.04, a quick ratio of 7.39 and a current ratio of 7.39.
WARNING: “Perceptive Advisors LLC Has $24.71 Million Stake in CymaBay Therapeutics Inc (CBAY)” was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.americanbankingnews.com/2018/03/12/perceptive-advisors-llc-has-24-71-million-stake-in-cymabay-therapeutics-inc-cbay.html.
CymaBay Therapeutics Company Profile
CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.